Personal profile
Personal profile
Lab Overview
The overall goal of our research is to discover ways to improve the treatment of epithelial ovarian cancer (EOC). Most cases of EOC are diagnosed at advanced stage when disease has spread beyond the ovary. From a clinical standpoint, EOC metastases and ascites production are perhaps the most significant cause of morbidity and mortality in patients because they can affect multiple vital organs in the abdominal cavity. At present, the cellular mechanisms regulating EOC metastasis remain only partially understood. Our laboratory is interested in defining molecular mechanisms that contribute to peritoneal dissemination of ovarian cancer cells to identify targets for therapeutic intervention in patients. Using a combination of in vitro and in vivo approaches, we hope to better understand EOC tumor biology at the cellular level as well as disease development and progression in animals. To facilitate our studies, we have developed a variety of transgenic and novel patient-derived mouse models of EOC. Several projects in our laboratory are focused on the cellular pathways involved in ovarian cancer cell migration, attachment and invasion with the ultimate goal of identifying therapeutic agents that inhibit the spread of ovarian cancer.
Research interests
- Mechanisms of ovarian cancer dissemination
- Targeted therapeutic strategies for treatment of ovarian cancer
- Development of mouse models of ovarian cancer
- Small animal imaging technologies
URL
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
In vivo 3D imaging of ovarian cancer outgrowth in transgenic mouse model with optical coherence tomography
Han, H., Mukhamedjanova, A., Connolly, D. C., Iwanicki, M. P. & Wang, S., Sep 1 2025, In: Journal of Biomedical Optics. 30, 9, p. 096007 096007.Research output: Contribution to journal › Article › peer-review
Open Access -
Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells
Madan, E., Palma, A. M., Vudatha, V., Kumar, A., Bhoopathi, P., Wilhelm, J., Bernas, T., Martin, P. C., Bilolikar, G., Gogna, A., Peixoto, M. L., Dreier, I., Araujo, T. F., Garre, E., Gustafsson, A., Dorayappan, K. D. P., Mamidi, N., Sun, Z., Yekelchyk, M. & Accardi, D. & 90 others, , Nov 2025, In: Nature Biotechnology. 43, 11, p. 1833-1847 15 p.Research output: Contribution to journal › Article › peer-review
15 Scopus citations -
Using Mendelian randomization to investigate etiologic heterogeneity across renal cell carcinoma subtypes
The Renal Cancer Genetics Consortium, Dec 1 2025, In: International Journal of Epidemiology. 54, 6, dyaf177.Research output: Contribution to journal › Article › peer-review
-
An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers
Xirou, V., Moutafi, M., Bai, Y., Nwe Aung, T., Burela, S., Liu, M., Kimple, R. J., Shabbir Ahmed, F., Schultz, B., Flieder, D., Connolly, D. C., Psyrri, A., Burtness, B. & Rimm, D. L., May 2024, In: Oral Oncology. 152, p. 106750 106750.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations -
Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma
Correa, A. F., Kalashnikova, E., Wu, H.-T., Winters, R. M., Balcioglu, M., Sudhaman, S., Connolly, D. C., Gong, Y., Uzzo, R. G., Sethi, H., ElNaggar, A. C., Aleshin, A., Liu, M. C. & Abbosh, P. H., Oct 3 2024, In: The oncologist. 29, 10, p. 887-893 7 p.Research output: Contribution to journal › Article › peer-review
Open Access16 Scopus citations
Press/Media
-
-
Fox Chase Cancer Center’s Biosample Repository Receives Reaccreditation From College of American Pathologists
03/12/25
1 Media contribution
Press/Media
-
Johns Hopkins: Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast Cancer
02/14/24 → 02/15/24
4 items of Media coverage
Press/Media
-
Johns Hopkins Medicine: Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast Cancer
02/15/24
1 item of Media coverage
Press/Media
-
Novel drug combination shows promise for advanced her2-negative breast cancer
02/14/24
4 items of Media coverage
Press/Media